Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Preliminary analyses of the samples provide no indication for a clinically relevant relationship between hyperprolactinemia and stimulation of adrenal steroidogenesis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to explore the effects of prolactin on adrenal steroid profiles in patients with hyperprolactinemia due to prolactinomas before and after initialisation of treatment.
Prolactin is known to influence many biological processes. One potential target is the adrenal gland, where prolactin may stimulate the production of adrenal steroid hormones. Conditions of increased prolactin production(hyperprolactinemia) could, therefore, increase concentrations of adrenal steroids. One of the potential implications would be false doping accusations of athletes engaging in elite sports.
This interaction between prolactin and adrenal steroidogenesis, however, remains poorly understood, and the available research findings are conflicting.
The investigators, therefore, seek to explore the relationship between prolactin and adrenal steroidogenesis by monitoring prolactin levels and blood and urinary steroid profiles of patients with hyperprolactinemia due to prolactinomas before and after treatment initialisation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Covariation of plasma prolactin and plasma dehydroepiandrosterone | Covariation of plasma prolactin and plasma dehydroepiandrosterone over time | From pre-treatment till 5 weeks of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Change in the plasma steroid profile | Change in the plasma steroid profile over time | From pre-treatment till 5 weeks of treatment |
| Change in plasma prolactin levels | Change in plasma prolactin levels over time |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study will involve up to 17 pre-menopausal female individuals with hyperprolactinemia due to prolactinomas, who will undergo treatment at the University Hospital Bern.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lia Bally, MD PhD | Inselspital, Bern University Hospital, University of Bern | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism, Inselspital, Bern University Hospital | Bern | 3010 | Switzerland |
Not provided
| ID | Term |
|---|---|
| D006966 | Hyperprolactinemia |
| ID | Term |
|---|---|
| D006964 | Hyperpituitarism |
| D010900 | Pituitary Diseases |
| D007027 | Hypothalamic Diseases |
| D001927 | Brain Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood and urine samples
| From pre-treatment till 5 weeks of treatment |
| Change in the urine steroid profile | Change in the urine steroid profile over time | From pre-treatment till 5 weeks of treatment |
| Covariation of urinary adrenal steroids | Covariation of urinary adrenal steroids over time | From pre-treatment till 5 weeks of treatment |
| D002493 |
| Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D004700 | Endocrine System Diseases |